Comparing Oliceridine and Sufentanil to Reduce Cough During General Anesthesia Induction A Randomized, Double-Blind Controlled Trial Evaluating Safety and Cough Incidence

What this Trial Is About

Researchers are studying cough triggered by sufentanil, a common opioid used during general anesthesia induction, which can cause serious safety risks like increased pressure in the brain and eyes, and unstable blood flow in high-risk patients. This Phase 4 randomized, double-blind trial compares oliceridine, a newer opioid designed to reduce cough by acting differently on opioid receptors, with sufentanil to assess differences in cough occurrence, severity, blood pressure changes, and overall safety during anesthesia induction. Participants will receive an intravenous bolus of either oliceridine or sufentanil based on age, administered over 2 seconds. After injection, cough will be monitored for 2 minutes. Following this, anesthesia will be completed using propofol and rocuronium, and tracheal intubation will be performed. The study is conducted in a single center with participants randomly assigned to one of the two groups, both patients and clinicians blinded to the treatment. During the trial, researchers will observe cough incidence and severity within 2 minutes after drug injection, measure heart rate and blood pressure from operating room entry until 10 minutes post-injection, and monitor any opioid-related adverse events such as breathing difficulties or low oxygen levels. The trial enrolls adults aged 18 to 99 undergoing elective surgery under general anesthesia, with a total participation duration covering the induction process and immediate postoperative monitoring, aiming to provide guidance on opioid selection for anesthesia induction.

Oliceridine vs Sufentanil for Cough During Anesthesia Induction